SVRA Strangle Strategy
SVRA (Savara Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA (Savara Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.17B, a beta of 0.26 versus the broader market, a 52-week range of 2.68-7.005, average daily share volume of 1.6M, a public-listing history dating back to 2017, approximately 70 full-time employees. These structural characteristics shape how SVRA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.26 indicates SVRA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on SVRA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
SVRA snapshot
As of August 14, 2026, spot at $5.38, ATM IV 69.00%, IV rank 12.00%, expected move 19.78%. The strangle on SVRA below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on SVRA specifically: SVRA IV at 69.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a SVRA strangle, with a market-implied 1-standard-deviation move of approximately 19.78% (roughly $1.06 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SVRA expiries trade a higher absolute premium for lower per-day decay. Position sizing on SVRA should anchor to the underlying notional of $5.38 per share and to the trader's directional view on SVRA stock.
SVRA strangle setup
The SVRA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SVRA at $5.38 on that close, the first option leg uses a $5.65 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SVRA chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SVRA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.65 | N/A |
| Buy 1 | Put | $5.11 | N/A |
SVRA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SVRA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SVRA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SVRA
Strangles on SVRA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SVRA chain.
SVRA thesis for this strangle
The market-implied 1-standard-deviation range for SVRA extends from approximately $4.32 on the downside to $6.44 on the upside. A SVRA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SVRA IV rank near 12.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SVRA at 69.00%. As a Healthcare name, SVRA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SVRA-specific events.
SVRA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SVRA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SVRA alongside the broader basket even when SVRA-specific fundamentals are unchanged. Always rebuild the position from current SVRA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SVRA?
- A strangle on SVRA is the strangle strategy applied to SVRA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SVRA stock at $5.38 on the most recent close, the strikes shown on this page are snapped to the nearest listed SVRA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are SVRA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SVRA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SVRA strangle?
- The breakeven for the SVRA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The SVRA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.78%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SVRA?
- Strangles on SVRA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SVRA chain.
- How does current SVRA implied volatility affect this strangle?
- SVRA ATM IV is at 69.00% with IV rank near 12.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.